



Health Technology Review		
Technology Ref.:	HTA20003	
Technology Name:	iSTOC Mobile Diagnostics and Analytics for Infectious at Point of Care (PoC)	
Approvals by International Bodies:	iSTOC COVID-19 IgM/IgG Rapid Diagnostics Test – CE Mark and PEUA, and FDA filed	
Company name:	iSTOC Diagnostics Solution	
Agent in UAE:	Emitac Healthcare Solution	
Email:	Bashar_Abughaush@emitac.ae	

Short Description of the Technology:	iSTOC (Finland) Mobile Diagnostics and Analytics for Infectious Diseases at Point of Care (PoC) integrates POC diagnostics, machine vision, mobile technology and cloud computing. The globally scalable end-to end solution has been proven to be a powerful tool in disease surveillance and surveillance data analytics. The iSTOC IDA (immediate diagnostics and analytics) IDR (infectious diseases reader) solution consists of a COVID-19 IgM/IgG rapid diagnostics test (RDT) kit, smartphone mobile reader application (IDR) and an analytics (IDA) backend solution. With very minimal instructions to untrained staff, the IDA-IDR solution can be deployed to capture digitized diagnostic data. The data can be verified and analyzed in 3 simple steps. The IDR mobile application can be used by a test operator at a point of care screening site or by a technician in the field. After the scan has been performed the results of the RDT are available immediately on both the IDA-IDR mobile application and the IDA backend service. This ensures the data is immediately available where it is actionable, either at the screening site or at a central care facility. IDA-IDR solution can also communicate directly with legacy healthcare
•	application can be used by a test operator at a point of care screening site or by a technician in the field. After the scan has been performed the results of the RDT are available immediately on both the IDA-IDR mobile application and the IDA backend service. This ensures the data is immediately available
	receive measurement results, treatments logs and any images describing potential problems or disease symptoms, via the IDA backend service. This enables a real-time consultation between the mobile application user and a healthcare professional at a central care facility.

Health Technology Assessment Team Recommendation:	Disapprove
Summary of Review:	





Advantages	Disadvantages
Low cost than PCR	Blood test is not effective and not accurate for COVID-19 detection
Rapid results obtained	Rapid test kits for COVID-19 in blood sample is still not approved
Easy to use and point of care test	Require confirmation with PCR
Use machine vision technology rather than human visual inspection	

We recommend a **disapproval of using this technology** due to the following:

1. Rapid test kits for COVID-19 using blood samples is not being proven its effectiveness

